Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Rev Esp Med Nucl ; 21(1): 17-23, 2002 Feb.
Artigo em Espanhol | MEDLINE | ID: mdl-11820997

RESUMO

A pilot study was carried out in the Nuclear Medicine Department of the National Institute of Oncology and Radiobiology to learn the diagnostic efficacy of the 99mTc-HMPAO scintigraphy in the detection of cutaneous melanoma, distant and local metastases, in patients with a confirmed histological diagnosis. The planar and/or SPECT scintigraphy was performed in 17 patients and revealed 90% sensitivity for the detection of the disease. We calculated the tumor/background index in all the images obtained and found a value greater than 1 in every case. Thus, we can affirm that the 99mTc-HMPAO accumulation in tumors was higher than the background in all cases. We recommend that this procedure be considered in the follow up of these patients as a new diagnostic method which is very useful in the determination of the patient stage and prognostic evaluation.


Assuntos
Melanoma/diagnóstico por imagem , Metástase Neoplásica/diagnóstico por imagem , Recidiva Local de Neoplasia/diagnóstico por imagem , Compostos Radiofarmacêuticos , Neoplasias Cutâneas/diagnóstico por imagem , Tecnécio Tc 99m Exametazima , Tomografia Computadorizada de Emissão de Fóton Único , Adulto , Idoso , Idoso de 80 Anos ou mais , Reações Falso-Negativas , Reações Falso-Positivas , Feminino , Seguimentos , Humanos , Masculino , Melanoma/patologia , Melanoma/cirurgia , Pessoa de Meia-Idade , Projetos Piloto , Sensibilidade e Especificidade , Neoplasias Cutâneas/patologia , Neoplasias Cutâneas/cirurgia
2.
Rev Esp Med Nucl ; 17(2): 82-8, 1998.
Artigo em Espanhol | MEDLINE | ID: mdl-9611277

RESUMO

A new Monoclonal Antibody (AcMo) ior-C5, highly specific for the most part of colorectal adenocarcinomas has been developed. The AcMo was labeled with 99mTc by the Schwarz's direct method using molar ratios MAb: reductant of 1:1,000 and 1:2,000. The first molar ratio was the most adequate for the preparation of the radiopharmaceutical. A labeling yield greater than 95% was obtained. Several <> assays were carried out in order to evaluate the stability of the preparation, whose results reflected the presence of the stable complex 99mTc-IgG. The biodistribution patterns for both preparations were similar. The excreting organs behaved like normal. Nevertheless, a greater renal excretion was observed for the preparation of the molar ratio of 1:2.000, which could be due to the presence of low affinity sites observed in this preparation. They are vulnerable to the trans-chelation of the 99mTc toward cysteine or glutathione present in plasma and tissues.


Assuntos
Adenocarcinoma/diagnóstico por imagem , Anticorpos Monoclonais , Neoplasias Colorretais/diagnóstico por imagem , Imunoconjugados , Radioimunodetecção , Compostos Radiofarmacêuticos , Tecnécio , Animais , Anticorpos Monoclonais/farmacocinética , Proteínas Sanguíneas/metabolismo , Cisteína/química , Estabilidade de Medicamentos , Humanos , Imunoconjugados/química , Imunoconjugados/farmacocinética , Rim/metabolismo , Masculino , Mercaptoetanol/farmacologia , Camundongos , Camundongos Endogâmicos BALB C , Oxirredução , Compostos Radiofarmacêuticos/farmacocinética , Substâncias Redutoras/farmacologia , Tecnécio/farmacocinética , Distribuição Tecidual
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA